Prevention and Management of XXXX .

@entity1 @entity64 @entity6249 @entity548 @entity73 @entity117 @entity1397 @entity3563 @entity1924 @entity1188 @entity1779 @entity62 @entity6817 @entity165
@entity1188 /lacunes, @entity62 ( @entity62 ), and cerebral microbleeds (CMBs) are considered various manifestations of @entity6249 ( @entity6249 ). Since the exact mechanisms of these manifestations differ, their associated risk factors differ. High blood pressure is the most consistent risk factor for all of these manifestations. However, a "J curve" phenomenon in terms of blood pressure probably exists for @entity62 . The association between @entity165 levels and @entity1188 /lacunes or @entity62 was less consistent and sometimes conflicting; a low @entity165 level probably increases the risk of CMBs. @entity3563 appears to be associated with @entity62 . It is noteworthy that the risk factors profile may also differ between different lacunar patterns and CMBs located at different parts of the brain. Thrombolysis, antihypertensives, and @entity6817 are used to treat @entity1 with symptomatic @entity1188 , just as in those with other @entity64 subtypes. However, it should be remembered that @entity548 risks increase in @entity1 with extensive @entity62 and CMBs after thrombolysis therapy. According to the Secondary Prevention of Small Subcortical Strokes trial results, a blood pressure reduction to <130 mmHg is recommended in @entity1 with symptomatic @entity1188 . However, an excessive blood pressure decrease may induce @entity73 in older @entity1 with extensive @entity62 . Dual antiplatelet therapy ( @entity117 plus @entity1397 ) should be avoided because of the excessive risk of @entity1779 . Although no particular antiplatelet is recommended, drugs such as @entity1924 or triflusal may have advantages for @entity1 with @entity6249 since they are associated with less frequent @entity548 complications than @entity117 .
